[Dose-intensive chemotherapy with continuous infusion 5-fluorouracil].
54 patients with advanced malignancy refractory to chemotherapy were studied to evaluate efficacy and toxicity of continuous infusion of 5-fluorouracil (5FU) given for 3 weeks. We report results of the first 156 courses given in combination with other drugs. 19 (37%) of the 54 responded, including 3 (6%) with complete response. Toxicity was acceptable, with mucositis in 13 (26%) and 3 (6%) with grade II-III toxicity. Results and toxicity profile were compatible with further disease-oriented studies using this dose-intensive program.
Tichler
T
T
Sheba Medical Center, Tel Hashomer.
Ghodsizade
E
E
Katz
A
A
Rath
P
P
Berger
R
R
Brenner
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D016190:Carboplatin / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D000964:Antimetabolites, Antineoplastic; D001761:Bleomycin; D016685:Mitomycin; D016190:Carboplatin; D002945:Cisplatin; D005472:Fluorouracil